1. Home
  2. MTA vs CBIO Comparison

MTA vs CBIO Comparison

Compare MTA & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTA
  • CBIO
  • Stock Information
  • Founded
  • MTA 1983
  • CBIO 2003
  • Country
  • MTA Canada
  • CBIO United States
  • Employees
  • MTA N/A
  • CBIO N/A
  • Industry
  • MTA
  • CBIO
  • Sector
  • MTA
  • CBIO
  • Exchange
  • MTA Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • MTA 279.4M
  • CBIO 308.0M
  • IPO Year
  • MTA N/A
  • CBIO N/A
  • Fundamental
  • Price
  • MTA $3.84
  • CBIO $16.31
  • Analyst Decision
  • MTA Hold
  • CBIO Strong Buy
  • Analyst Count
  • MTA 1
  • CBIO 2
  • Target Price
  • MTA $4.50
  • CBIO $25.00
  • AVG Volume (30 Days)
  • MTA 501.6K
  • CBIO 52.2K
  • Earning Date
  • MTA 08-13-2025
  • CBIO 08-23-2025
  • Dividend Yield
  • MTA N/A
  • CBIO N/A
  • EPS Growth
  • MTA N/A
  • CBIO N/A
  • EPS
  • MTA N/A
  • CBIO N/A
  • Revenue
  • MTA $6,348,000.00
  • CBIO N/A
  • Revenue This Year
  • MTA $125.91
  • CBIO N/A
  • Revenue Next Year
  • MTA $58.98
  • CBIO N/A
  • P/E Ratio
  • MTA N/A
  • CBIO N/A
  • Revenue Growth
  • MTA 30.38
  • CBIO N/A
  • 52 Week Low
  • MTA $2.32
  • CBIO $11.06
  • 52 Week High
  • MTA $4.08
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • MTA 63.55
  • CBIO N/A
  • Support Level
  • MTA $3.65
  • CBIO N/A
  • Resistance Level
  • MTA $3.98
  • CBIO N/A
  • Average True Range (ATR)
  • MTA 0.17
  • CBIO 0.00
  • MACD
  • MTA 0.01
  • CBIO 0.00
  • Stochastic Oscillator
  • MTA 73.98
  • CBIO 0.00

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: